Matinas Biopharma Holdings, INC 8-K filings

Matinas BioPharma Holdings, Inc. announced the immediate termination of its At-The-Market Sales Agreement with BTIG, LLC, effective July 23, 2026, with no associated termination penalties.

Matinas BioPharma Holdings, Inc. announces a strategic business combination with GH Power Inc. to form a clean energy company, alongside the sale of its LNC platform and MAT2203 to Azurity Pharmaceuticals.

Matinas BioPharma has been granted a compliance plan period until October 2027 by the NYSE American following notice of non-compliance with stockholders' equity standards.

Matinas BioPharma Holdings, Inc. received a notice from NYSE American for failing to meet continued listing standards, with a deadline to submit a compliance plan.

Matinas BioPharma Holdings, Inc. announced that its CEO, Jerome D. Jabbour, will assume the interim Chief Financial Officer role following the resignation of Keith Kucinski.

Matinas BioPharma Holdings, Inc. has amended its CEO's employment agreement, extending retention bonus triggers and modifying change-in-control definitions.

Matinas BioPharma Holdings, Inc. announced the resignation of its Chief Financial Officer, Keith Kucinski, effective January 17, 2026.

Matinas BioPharma Holdings, Inc. exchanged 466,666 outstanding warrants for an equal number of common shares, cancelling the warrants.

Matinas BioPharma Holdings, Inc. has increased its authorized common stock from 250 million to 500 million shares, effective August 6, 2025.

Matinas BioPharma Holdings, Inc. stockholders approved a potential reverse stock split, an increase in authorized common stock, and a new 2025 Equity Incentive Plan at their annual meeting on June 23, 2025.

Matinas BioPharma Holdings, Inc. has amended its bylaws to reduce quorum requirements for stockholder meetings and has also amended employment agreements for key executives to include retention bonuses in the event of a change in control.

Matinas BioPharma Holdings, Inc. finalized a private placement offering, raising a total of $3.3 million through the sale of Series C Convertible Preferred Stock and warrants.

Matinas BioPharma stockholders approved the issuance of common stock upon conversion of preferred stock and ratification of the company's accounting firm at a special meeting held on April 4, 2025.

Eric Ende resigned from Matinas BioPharma Holdings' Board of Directors and as Chairman, effective March 14, 2025, due to other professional obligations.

Matinas BioPharma Holdings appoints Keith Murphy and Edward Neugeboren to its Board of Directors, while Matthew Wikler and Natasha Giordano step down, effective March 11, 2025.

Matinas BioPharma announces a $3.3 million securities purchase agreement and the appointment of Dr. Robin L. Smith to its Board of Directors.

Herbert Conrad resigned from Matinas BioPharma Holdings' Board of Directors, effective February 6, 2025, due to retirement.

Matinas BioPharma Holdings, Inc. appoints Evelyn D'An to its Board of Directors as an independent director and Chair of the Audit Committee, effective February 5, 2025.

James S. Scibetta resigned from the Board of Directors of Matinas BioPharma Holdings, Inc. effective immediately due to other professional obligations.

Matinas BioPharma received a notice from the NYSE American for failing to hold its annual meeting of stockholders, potentially impacting its listing status.

Kathryn Penkus Corzo has resigned from the Board of Directors of Matinas BioPharma Holdings, Inc., effective immediately, due to other professional commitments.

Matinas BioPharma has terminated its product development activities and reduced its workforce by 80% after a partnership deal for its lead drug candidate, MAT2203, fell through.

Matinas BioPharma's Chief Development Officer, Theresa Matkovits, Ph.D., has resigned effective October 23, 2024, to pursue another opportunity.

Matinas BioPharma has executed a 1-for-50 reverse stock split and reduced its authorized shares from 500 million to 250 million, effective August 30, 2024.

Matinas BioPharma's stock trading was halted by the NYSE American due to its low price, and the company plans a 1-for-50 reverse stock split to regain compliance.

Matinas BioPharma has announced a 1-for-50 reverse stock split and a reduction in authorized shares, effective August 30, 2024, to maintain NYSE American listing compliance.

Matinas BioPharma reported its second quarter 2024 financial results, highlighted by a non-binding term sheet for global licensing of MAT2203 and progress in its compassionate use program.

Matinas BioPharma announced its first quarter 2024 financial results, highlighting a recent $10 million financing and ongoing partnership discussions for its lead drug candidate, MAT2203.

Matinas BioPharma has entered into agreements for a $10 million registered direct offering of common stock and warrants to healthcare-focused institutional investors.

Matinas BioPharma Holdings, Inc. has released an updated corporate presentation to be used at upcoming conferences and investor meetings.